Home Newsfeeds Loop Capital Maintains Buy on AMETEK, Lowers Price Target to $155

Loop Capital Maintains Buy on AMETEK, Lowers Price Target to $155

Loop Capital analyst Scott Graham maintains AMETEK (NYSE:AME) with a Buy and lowers the price target from $170 to $155.

byBenzinga Newsdesk

July 19, 2022

1 minute read

Loop Capital analyst Scott Graham maintains AMETEK (NYSE:AME) with a Buy and lowers the price target from $170 to $155.

Predictive Oncology And Cancer Research Horizons Have Partnered To Drive The Development Of Oncology Drugs Utilizing Predictive Oncology’s PEDAL Platform

By Benzinga Newsdesk

March 17, 7:02 AM

The collaboration will utilize Predictive Oncology's PEDAL technology to evaluate Cancer Research Horizons' pre-clinical drug inhibitors of Glutaminase in order to determine which cancer types and patient

POAI

Analyst Ratings

Demystifying Chesapeake Energy: Insights From 6 Analyst Reviews

By Benzinga Insights

January 3, 11:01 AM

During the last three months, 6 analysts shared their evaluations of Chesapeake Energy (NASDAQ:CHK), revealing diverse outlooks from…

CHK

Kimberly-Clark’s Long Term Outlook, Cost Savings Plan Looks Encouraging, Analyst Says

By Shivani Kumaresan

March 28, 2:12 PM

Piper Sandler's Korinne Wolfmeyer raises Kimberly-Clark price target amid strategic shift. With plans to reinvest $200M in savings, KMB targets growth through recruitment moments and global scaling.

KMB

Ascendis Pharma Announces Topline Results From TransCon hGH Achieved Statistically Superior Outcomes Compared To Placebo In Phase 3 foresiGHt Trial Of Adults With Growth Hormone Deficiency

By Benzinga Newsdesk

December 19, 9:35 AM

– On primary efficacy and key secondary endpoints, TransCon hGH demonstrated statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo

ASND

Loop Capital Maintains Buy on AMETEK, Lowers Price Target to $155

Related Posts

Predictive Oncology And Cancer Research Horizons Have Partnered To Drive The Development Of Oncology Drugs Utilizing Predictive Oncology’s PEDAL Platform

Demystifying Chesapeake Energy: Insights From 6 Analyst Reviews

Kimberly-Clark’s Long Term Outlook, Cost Savings Plan Looks Encouraging, Analyst Says

Ascendis Pharma Announces Topline Results From TransCon hGH Achieved Statistically Superior Outcomes Compared To Placebo In Phase 3 foresiGHt Trial Of Adults With Growth Hormone Deficiency